Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, NHC Key Laboratory of Thrombosis and Hemostasis, The First Affiliated Hospital of Soochow University, Soochow University, Suzhou, P.R China.
Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
Mol Carcinog. 2021 Nov;60(11):721-725. doi: 10.1002/mc.23333. Epub 2021 Jul 8.
Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia (AML), which is characterized by the reciprocal t (15;17) (q24; q21) translocation, resulting in PML-RARA gene fusion. Therapy-related AML (t-AML) is a serious complication after cytotoxic and/or radiation therapy in many malignant diseases. In this report, MLL/KMT2A-MON2, with balanced chromosomal translocation t (11;12) (q23; q14), was identified as a novel fusion in a child transformed to t-AML after successful treatment of APL. This study emphasized that clinical monitoring with an integrated laboratory approach is essential for the diagnosis and treatment of t-AML.
急性早幼粒细胞白血病（APL）是一种独特的急性髓系白血病（AML）亚型，其特征为相互易位 t（15；17）（q24；q21），导致 PML-RARA 基因融合。治疗相关性急性髓系白血病（t-AML）是许多恶性疾病接受细胞毒性和/或放射治疗后的严重并发症。在本报告中，鉴定出 MLL/KMT2A-MON2，具有平衡染色体易位 t（11；12）（q23；q14），是在成功治疗 APL 后发生 t-AML 的儿童中的一种新型融合。本研究强调，临床监测与综合实验室方法对于 t-AML 的诊断和治疗至关重要。
